The 36th EORTC-NCI-AACR (ENA) Symposium took place at the CCIB in Barcelona from October 23-24, 2024 and presented the latest results on molecular targets and cancer therapeutics. Stephen Pettitt presented translational research results on the persistence of BRCA1 and RAD51C methylation after neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) at high risk of relapse.
The study used samples from TNBC patients who had residual disease after neoadjuvant chemotherapy (NACT). The samples were obtained from a variety of sources, including NACT clinical trials (GeparOla, GeparSixto, from the GBG and AGO-B trials groups), observational clinical studies (BTBC, ChemoNear, FRCB) and biobanks (Breast Cancer Now Tissue Bank; BCNTB).
The poster can be downloaded here: